FGFR2 and skin squamous cell carcinoma: Recent studies have shown that selective FGFR inhibitors, such as AZD4547, can reduce UVB-induced FGFR2 activation and subsequent epidermal hyperplasia, highlighting its potential as a therapeutic target in cSCC.